PDCD1 and neoplasm: The decreased expression of major histocompatibility complex (MHC) class I, low tumor mutation burden, low PD-1 expression, chronic activation of the interferon-1 (IFN-1), and PTEN loss adversely affect the tumor microenvironment and immunotherapy outcomes [38,41,83].